Mac Overmyer
Men with significant comorbidities overtreated for prostate cancer
A recent study suggests that a substantial portion of men with comorbidities serious enough to affect their lifespan are also being subjected to likely unnecessarily aggressive therapy.
Meshless cystocele repair shows promise
A new meshless cystocele repair procedure intended to circumvent the problems seen with traditional repair appears to be durable and cost effective.
Successful urethral stricture, fistula repair feasible in most cases
Managing the urethral strictures and fistulas that sometimes follow prostate cancer therapies can be intimidating, but with experience, the presentations can be resolved with high success in a near majority of patients.
Most post-radical prostatectomy erectile dysfunction cases have non-neurogenic etiology
The advent of nerve-sparing radical prostatectomy and its outcomes has focused attention on the etiology of erectile dysfunction following all forms of prostate cancer intervention.
Post-radical prostatectomy erectile function recovery lower than reported
Post-radical prostatectomy erectile function recovery is much lower than physician-reported rates, a study indicates.
Pre-radical prostatectomy penile length returns by 4 years after surgery
Researchers found that stretched penile length following radical prostatectomy for prostate cancer decreased until 36 months post-op, then at this point, the process appears to reach a nadir and reverse itself so that by 48 months, stretched length appeared to be fully restored at 5 years post-op.
Modified patient position for percutaneous nephrolithotomy shows advantages
Placing a patient in a "prone-flexed" position offers a number of benefits for percutaneous nephrolithotomy.
Prototype ultrasound device images, moves kidney stones
A team at the University of Washington School of Medicine and Applied Physics Lab, Seattle, is refining prototype technology that should allow extracorporeal ultrasound to image and, more importantly, move stones in a kidney as if they were being nudged gently by a pool cue.
Active surveillance for prostate cancer results in cost savings
According to one well-refined simulation model, the cost in current dollars of treating 100 prostate cancer patients initially enlisted in an active surveillance program is $2,702,191 over 5 years. This is $1,013,422 less expensive per 100 men than any of the available immediate interventional therapies over the same span and could translate to substantial national savings.
Embolization for benign prostatic hyperplasia yields strong outcomes
An embolization technique employing 100-?m or 200-?m polyvinyl beads delivered through the femoral artery and into prostatic arteries to block the latter and shrink prostate volume in men with BPH produces short- and mid-term results equivalent to transurethral resection of the prostate.


View Results